Absolute quantification of KRAS G12D using LNA probes
Learn how Bioke used Horizon Reference Standards to determine the lower limit of detection of the Raindrop dPCR system when quantifying KRAS G12D
Approximately 15–25% of patients with lung adenocarcinoma have tumour associated KRAS mutations, which are negative predictors of radiographic response to the EGFR tyrosine kinase inhibitors such as erlotinib or gefitinib. KRAS detection can therefore be used to determine the treatment strategy of a patient. In this application note, Bioke use Horizon Reference Standards to test the lower limit of detection of their Locked Nucleic Acid (LNA) probe based KRAS G12D detection assay on the Raindrop dPCR platform.
Where should we send the application note?
* Indicates a required field
